Bimekizumab efficacy

Three major studies show that bimekizumab can be used to treat moderate to severe plaque psoriasis in adults. Patients with plaque psoriasis who received bimezumab improved more than those who received placebo (dummy treatment) or two other psoriasis drugs (ustekinumab or adalimumab).

In three studies involving a total of 1,480 patients, about 85% to 91% of people who received bimezumab every four weeks achieved about 90% reductions in PASI scores (a measure of psoriasis severity and affected skin area) after 16 weeks. In comparison, 1-5% of patients received placebo, 50% received ustekinumab, and 47% received adalimumab. Additionally, 84-93% of patients who received bimezumab had clear or nearly clear skin after 16 weeks, compared with 1-5% of patients who received placebo, 53% of patients who received ustekinumab, and 57% of patients who received adalimumab.

In two major studies of approximately 1,100 patients with psoriatic arthritis, including those taking methotrexate, bimelizumab was effective in reducing symptoms, as measured using a standard metric called ACR50. Patients who achieved an ACR50 response had at least a 50% improvement in symptom scores of joint pain and swelling. Taken together, the results from these two studies showed that 44% of patients treated with bimeclizumab achieved an ACR50 response after 16 weeks, compared with only 9% of patients treated with placebo (dummy treatment).

Two major studies in patients with axial spondyloarthritis showed that bimelizumab was effective in reducing symptoms after 16 weeks when measured using a standard metric called ASAS40. Patients who achieved an ASAS40 response experienced at least a 40% improvement in scores for symptoms such as pain and inflammation.

In one study involving254 patients with non-radiographic axial spondyloarthritis, 48% of patients who received bimeclizumab achieved an ASAS40 response, compared with 21% of patients who received placeboASAS40 Response (Virtual Therapy). In the second study, involving 332 patients with radiographic axial spondyloarthritis, 45% of patients treated with bimezumab achieved an ASAS40 response, compared with 23% of patients treated with placebo.

The generic drug Bimeizumab has not yet been launched in the country, so it cannot be included in medical insurance. The European version of bimezumab original drug sold overseas, specifications160mg*2 per box may cost more than 40,000 yuan (the price may fluctuate due to the exchange rate). The price is still relatively high. There is currently no generic version of bimezumab produced and launched. For the specific price and drug information of this drug, please consult a medical consultant.